{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T22:23:43Z","timestamp":1774995823274,"version":"3.50.1"},"reference-count":40,"publisher":"Tech Science Press","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["oncol res"],"published-print":{"date-parts":[[2018,3,5]]},"abstract":"<jats:p>In this retrospective review of a single institution\u2019s experience, the efficacy and safety of the long-term use of nimotuzumab in combination with intensity-modulated radiotherapy (IMRT) and chemotherapy in the treatment of locally advanced nasopharyngeal carcinoma (NPC) were\n studied. Between August 2008 and March 2014, 39 newly diagnosed patients with stages III\u2010IV NPC were treated with IMRT, chemotherapy, and nimotuzumab. Twenty patients were diagnosed with stage III (51.3%), 14 with stage IVA (35.9%), and 5 with stage IVB (12.8%) disease. All patients\n received at least one cycle of cisplatin-based induction chemotherapy followed by IMRT and more than nine cycles of nimotuzumab at 200 mg\/week. Acute and late radiation-related toxicities were graded according to the Acute and Late Radiation Morbidity Scoring Criteria of the Radiation Therapy\n Oncology Group. Accumulated survival was calculated according to the Kaplan\u2010Meier method. The log-rank test was used to compare survival differences. With a median follow-up of 46 months (range, 22\u201086 months), the estimated 3-year local recurrence-free, regional recurrence-free,\n distant metastasis-free, progression failure-free, and overall survival rates were 92.1%, 89.7%, 82.5%, 77.6%, and 86.8%, respectively. Univariate analysis showed that clinical stage and the cycle of induction chemotherapy were related with prognosis. The median cycle for the addition of nimotuzumab\n was 12 weeks. Grade 3 radiation-induced mucositis was observed in 15.8% of the treated patients. No skin rash or infusion reaction was observed, which is distinctly different from what was reported in patients treated with nimotuzumab. The major toxicities observed were grades I\u2010II\n mucositis and leukocytopenia. Long-term use of nimotuzumab plus IMRT showed promising outcomes in terms of locoregional control and survival, without increasing the incidence of radiation-related toxicities in patients.<\/jats:p>","DOI":"10.3727\/096504017x15079846743590","type":"journal-article","created":{"date-parts":[[2017,10,19]],"date-time":"2017-10-19T01:10:48Z","timestamp":1508375448000},"page":"277-287","source":"Crossref","is-referenced-by-count":14,"title":["Long-Term Use of Nimotuzumab in Combination With Intensity-Modulated Radiotherapy and Chemotherapy in the Treatment of Locoregionally Advanced Nasopharyngeal Carcinoma: Experience of a Single Institution"],"prefix":"10.32604","volume":"26","author":[{"given":"Wang","family":"Fangzheng","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Zhejiang Cancer Hospital, Zhejiang, Hangzhou, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiang","family":"Chuner","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, Zhejiang Cancer Hospital, Zhejiang, Hangzhou, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ye","family":"Zhiming","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Zhejiang Cancer Hospital, Zhejiang, Hangzhou, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liu","family":"Tongxin","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Zhejiang Cancer Hospital, Zhejiang, Hangzhou, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Fengqin","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Zhejiang Cancer Hospital, Zhejiang, Hangzhou, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wang","family":"Lei","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Zhejiang Cancer Hospital, Zhejiang, Hangzhou, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Bin","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Zhejiang Cancer Hospital, Zhejiang, Hangzhou, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hu","family":"Fujun","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Zhejiang Cancer Hospital, Zhejiang, Hangzhou, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen","family":"Ming","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Zhejiang Cancer Hospital, Zhejiang, Hangzhou, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qin","family":"Weifeng","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Zhejiang Cancer Hospital, Zhejiang, Hangzhou, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fu","family":"Zhenfu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Zhejiang Cancer Hospital, Zhejiang, Hangzhou, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"17807","reference":[{"key":"b1","doi-asserted-by":"crossref","first-page":"114","DOI":"10.5732\/cjc.010.10377","article-title":"The prevalence and prevention of nasopharyngeal carcinoma in China","volume":"30","year":"2011","journal-title":"Chin J Cancer"},{"key":"b2","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1158\/1055-9965.EPI-06-0353","article-title":"The enigmatic epidemiology of nasopharyngeal carcinoma","volume":"15","year":"2006","journal-title":"Cancer Epidemiol Biomarkers Prev."},{"key":"b3","doi-asserted-by":"crossref","first-page":"4604","DOI":"10.1200\/JCO.2004.10.074","article-title":"The additional value of chemotherapy to radiotherapy in locally advanced nasopharyngeal carcinoma, a meta-analysis of the published literature","volume":"22","year":"2004","journal-title":"J Clin Oncol."},{"key":"b4","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ijrobp.2005.06.037","article-title":"Chemotherapy in locally advanced nasopharyngeal carcinoma, an individual patient data meta-analysis of eight randomized trials and 1753 patients","volume":"64","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"b5","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1200\/JCO.1998.16.4.1310","article-title":"Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: Phase III randomized intergroup study 0099","volume":"16","year":"1998","journal-title":"J Clin Oncol."},{"key":"b6","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.oraloncology.2013.11.008","article-title":"Nimotuzumab provides survival benefit to patients with inoperable advanced squamous cell carcinoma of the head and neck: A randomized, open-label, phase IIb, 5-year study in Indian patients","volume":"50","year":"2014","journal-title":"Oral Oncol."},{"key":"b7","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1002\/cncr.10372","article-title":"Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: A new paradigm for cancer therapy","volume":"94","year":"2002","journal-title":"Cancer"},{"key":"b8","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ijrobp.2003.10.038","article-title":"Prognostic value of epidermal growth factor receptor expression in patients with advanced stage nasopharyngeal carcinoma treated with induction chemotherapy and radiotherapy","volume":"59","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"b9","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1002\/hed.10307","article-title":"Prognostic significance of tumor angiogenesis, Ki 67, p53 oncoprotein, epidermal growth factor receptor and HER2 receptor protein expression in undifferentiated nasopharyngeal carcinoma\u2014A prospective study","volume":"25","year":"2003","journal-title":"Head Neck"},{"key":"b10","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/00005537-200401000-00029","article-title":"Epidermal growth factor receptor in undifferentiated carcinoma of the nasopharynx","volume":"114","year":"2004","journal-title":"Laryngoscope"},{"key":"b11","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s40265-013-0025-3","article-title":"Promising new molecular targeted therapies in head and neck cancer","volume":"73","year":"2013","journal-title":"Drugs"},{"key":"b12","first-page":"510","article-title":"Afatinib, erlotinib and gefitinib in the first-line therapy of EGFR mutation-positive lung adenocarcinoma: A review","volume":"36","year":"2013","journal-title":"Onkologie"},{"key":"b13","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s11523-013-0281-x","article-title":"Role of targeted agents in metastatic colorectal cancer","volume":"8","year":"2013","journal-title":"Targeted Oncol."},{"key":"b14","doi-asserted-by":"crossref","first-page":"8690","DOI":"10.1016\/j.biomaterials.2013.07.100","article-title":"Epidermal growth factor receptor targeting in cancer: A review of trends and strategies","volume":"34","year":"2013","journal-title":"Biomaterials"},{"key":"b15","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S1470-2045(09)70311-0","article-title":"Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-Year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival","volume":"11","year":"2010","journal-title":"Lancet Oncol."},{"key":"b16","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1007\/s12032-014-0170-x","article-title":"Toxicity of concurrent chemoradiotherapy with cetuximab for locoregionally advanced nasopharyngeal carcinoma","volume":"31","year":"2014","journal-title":"Med Oncol."},{"key":"b17","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1093\/annonc\/mdr401","article-title":"A phase II study of concurrent cetuximab-cisplatin and intensity-modulated radiotherapy in locoregionally advanced nasopharyngeal carcinoma","volume":"23","year":"2012","journal-title":"Ann Oncol."},{"key":"b18","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.2217\/fon.13.151","article-title":"Cetuximab in combination with chemoradiation after induction chemotherapy of locoregionally advanced nasopharyngeal carcinoma: Preliminary results","volume":"9","year":"2013","journal-title":"Future Oncol."},{"key":"b19","doi-asserted-by":"crossref","first-page":"5851","DOI":"10.1158\/0008-5472.CAN-08-4518","article-title":"Nimotuzumab, an antitumor antibody that targets the epidermal growth factor receptor, blocks ligand binding while permitting the active receptor conformation","volume":"69","year":"2009","journal-title":"Cancer Res."},{"key":"b20","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1200\/JCO.2004.03.089","article-title":"Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients","volume":"22","year":"2004","journal-title":"J Clin Oncol."},{"key":"b21","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/00002371-200303000-00006","article-title":"Pharmacological evaluation of humanized anti-epidermal growth factor receptor, monoclonal antibody h-R3, in patients with advanced epithelial-derived cancer","volume":"26","year":"2003","journal-title":"J Immunother."},{"key":"b22","doi-asserted-by":"crossref","first-page":"e958","DOI":"10.1097\/MD.0000000000000958","article-title":"S-1 and cisplatin with or without nimotuzumab for patients with untreated unresectable or metastatic gastric cancer: A randomized, open-label phase 2 trial","volume":"94","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"b23","first-page":"197","article-title":"A phase II study of (clinical study of) anti-epidermal growth factor receptor monoclonal antibody h-R3 combined with radiotherapy in the treatment of advanced nasopharyngeal carcinoma","volume":"29","year":"2007","journal-title":"Chin J Oncol."},{"key":"b24","doi-asserted-by":"crossref","first-page":"343","DOI":"10.4161\/cbt.9.5.10981","article-title":"Nimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neck","volume":"9","year":"2010","journal-title":"Cancer Biol Ther."},{"key":"b25","doi-asserted-by":"crossref","first-page":"24429","DOI":"10.18632\/oncotarget.8225","article-title":"Nimotuzumab combined with concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma: A retrospective analysis","volume":"7","year":"2016","journal-title":"Oncotarget"},{"key":"b26","first-page":"3383","article-title":"Experience with combination of nimotuzumab and intensity-modulated radiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma","volume":"8","year":"2015","journal-title":"Onco Targets Ther."},{"key":"b27","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1089\/cbr.2013.1591","article-title":"Prolonged use of nimotuzumab in children with central nervous system tumors: Safety and feasibility","volume":"29","year":"2014","journal-title":"Cancer Biother Radiopharm."},{"key":"b28","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1002\/1097-0142(19930415)71:8<2689::AID-CNCR2820710843>3.0.CO;2-H","article-title":"The World Health Organization histological classification of tumors of the upper respiratory tract and ear. A commentary on the second edition","volume":"71","year":"1993","journal-title":"Cancer"},{"key":"b29","volume-title":"Prescribing, recording, and reporting photon beam therapy","year":"1993"},{"key":"b30","volume-title":"Prescribing, recording, and reporting photon beam therapy (supplement to ICRU report 50)","year":"1999"},{"key":"b31","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ijrobp.2005.07.968","article-title":"Preliminary results of radiation dose escalation for locally advanced nasopharyngeal carcinoma","volume":"64","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"b32","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.ijrobp.2009.11.024","article-title":"Clinical outcomes and patterns of failure after intensity-modulated radiotherapy for nasopharyngeal carcinoma","volume":"79","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"b33","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1007\/s00432-013-1419-z","article-title":"Experience with combination of cetuximab plus intensity-modulated radiotherapy with or without chemotherapy for locoregionally advanced nasopharyngeal carcinoma","volume":"139","year":"2013","journal-title":"J Cancer Res Clin Oncol."},{"key":"b34","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1186\/s12885-016-2661-y","article-title":"Induction chemotherapy followed by radiotherapy versus concurrent chemoradiotherapy in elderly patients with nasopharyngeal carcinoma: Finding from a propensity-matched analysis","volume":"16","year":"2016","journal-title":"BMC Cancer"},{"key":"b35","doi-asserted-by":"crossref","first-page":"5123","DOI":"10.2147\/OTT.S103729","article-title":"Comparison of the short-term efficacy between docetaxel plus carboplatin and 5-fluorouracil plus carboplatin in locoregionally advanced nasopharyngeal carcinoma","volume":"9","year":"2016","journal-title":"Onco Targets Ther."},{"key":"b36","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.tranon.2016.06.003","article-title":"Outcomes of induction chemotherapy plus intensity-modulated radiotherapy (IMRT) versus IMRT plus concurrent chemotherapy for locoregionally advanced nasopharyngeal carcinoma: A propensity matched study","volume":"9","year":"2016","journal-title":"Transl Oncol."},{"issue":"11","key":"b37","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/S1470-2045(16)30410-7","article-title":"Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: A phase 3, multicentre, randomised controlled trial","volume":"17","year":"2016","journal-title":"Lancet Oncol."},{"key":"b38","doi-asserted-by":"crossref","first-page":"41","DOI":"10.4161\/mabs.1.1.7509","article-title":"Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin","volume":"1","year":"2009","journal-title":"MAbs"},{"key":"b39","first-page":"836","article-title":"Effect of nimotuzumab on the radiation sensitivity of nasopharyngeal carcinoma cell line CNE-2","volume":"33","year":"2011","journal-title":"Chin J Zhejiang Med."},{"key":"b40","doi-asserted-by":"crossref","first-page":"96798","DOI":"10.18632\/oncotarget.18245","article-title":"Gemcitabine\/cisplatin induction chemotherapy before concurrent chemotherapy and intensity-modulated radiotherapy improves outcomes for locoregionally advanced nasopharyngeal carcinoma","volume":"8","year":"2017","journal-title":"Oncotarget."}],"container-title":["Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.techscience.com\/uploads\/attached\/file\/20240524\/20240524104447_22003.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T21:36:12Z","timestamp":1733520972000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.techscience.com\/or\/v26n2\/56639"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,5]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,3,5]]}},"alternative-id":["0965-0407(20180305)26:2L.277;1-"],"URL":"https:\/\/doi.org\/10.3727\/096504017x15079846743590","relation":{},"ISSN":["0965-0407"],"issn-type":[{"value":"0965-0407","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3,5]]}}}